<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01406665</url>
  </required_header>
  <id_info>
    <org_study_id>SAF-tree-IGTDM11</org_study_id>
    <secondary_id>METc 2009-367</secondary_id>
    <nct_id>NCT01406665</nct_id>
  </id_info>
  <brief_title>Skin Autofluorescence (AF) Decision Tree in Detecting Impaired Glucose Tolerance (IGT) or Diabetes Mellitus (DM)</brief_title>
  <official_title>Assessment of Value of Skin Autofluorescence in Detecting Diabetes Mellitus or Impaired Glucose Tolerance. Comparison With Fasting Plasma Glucose and Glycated Hb</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Early detection of (pre)diabetes, including impaired glucose tolerance is currently deficient&#xD;
      because the best accepted standard, an oral glucose tolerance test (oGTT), is not feasible in&#xD;
      a setting of screening or broad case-finding and other current methods lack in sensitivity. A&#xD;
      previously reported study, and analysis of retrospective skin autofluorescence (AF) data,&#xD;
      suggests that noninvasive skin AF may offer an alternative for detection of (pre)diabetes.&#xD;
      The objective is to test the validity of a decision tree based on skin autofluorescence, and&#xD;
      some simple clinical characteristics, as a detection tool for diabetes and impaired glucose&#xD;
      tolerance. Sensitivity and specificity, positive and negative predictive value of this skin&#xD;
      AF based decision model will be compared to those of fasting plasma glucose (FPG), glycated&#xD;
      haemoglobin (HbA1c), and to two short questionnaires (Finnish Findrisk, and Cambridge score).&#xD;
&#xD;
      Study design: Skin AF, HbA1c and an oGTT (including an FPG) will be simultaneously performed&#xD;
      in at least 120 persons with the characteristics described in the following paragraph. A&#xD;
      Findrisk and Cambridge questionnaire will also be collected.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>oGTT (WHO criteria)-defined impaired glucose tolerance or diabetes</measure>
    <time_frame>individually immediately following test, for study &lt;26 weeks</time_frame>
    <description>numbers of true and false positives and negatives for oGTT (WHO criteria)-defined impaired glucose tolerance or diabetes are scored for Skin autofluorescence (based decision tree), FPG and HbA1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Findrisk diabetes questionnaire score</measure>
    <time_frame>individually immediately after test, for study &lt;26 weeks</time_frame>
    <description>Findrisk diabetes questionnaire score is based on anthropometric data and questionnaire.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">218</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>increased diabetes risk</arm_group_label>
    <description>the recruited group consists of persons with moderate to high risk for impaired glucose tolerance or diabetes</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      none retained&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects identified from an outpatient (vascular, lipid) hospital-based group, with an&#xD;
        intermediate risk of (pre)diabetes, as defined by an age &gt;35 years, and additionally at&#xD;
        least one criterion from the metabolic syndrome, or at least once an increased glucose or&#xD;
        HbA1c value in the preceding two years, but these outside the range of diabetes/IGT&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria: -age &gt;20 years&#xD;
&#xD;
          -  additionally a priori intermediate risk for IGT/diabetes: by having at least one&#xD;
             criterion from the metabolic syndrome, or by at least once having had an increased&#xD;
             glucose or glycated hemoglobin value in the preceding two years, but these outside the&#xD;
             range of diabetes/IGT&#xD;
&#xD;
        Exclusion Criteria:-known diabetes mellitus&#xD;
&#xD;
          -  use of oral antidiabetics for other purposes than diabetes such as hepatic steatosis&#xD;
&#xD;
          -  local skin disease of the lower arm obviating skin autofluorescence measurement&#xD;
&#xD;
          -  known serious renal insufficiency (s-creatinine &gt; 180 umol/l).&#xD;
&#xD;
          -  inability to fill in questionnaires&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gelre Ziekenhuis</name>
      <address>
        <city>Apeldoorn</city>
        <state>Gelderland</state>
        <zip>7334 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>July 28, 2011</study_first_submitted>
  <study_first_submitted_qc>July 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2011</study_first_posted>
  <last_update_submitted>July 29, 2011</last_update_submitted>
  <last_update_submitted_qc>July 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. R.O.B. Gans, Head of Department Internal medicine</name_title>
    <organization>University medical Center Groningen Dept medicine</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>impaired glucose tolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

